1/11/2021 8:30:32 AM
Karyopharm Expects Q4 Total Revenues To Be $35.0 Mln - $36.0 Mln
12/20/2020 7:49:31 PM
Karyopharm Therapeutics Gets FDA Approval Of XPOVIO As Treatment For Patients With Multiple Myeloma
12/15/2020 7:14:36 AM
Karyopharm Therapeutics Appoints Michael Mano As SVP, General Counsel
12/1/2020 7:51:39 AM
Karyopharm Appoints Chen Schor To Its Board, Stephen Mitchener Chief Business Officer
11/25/2020 7:06:06 AM
Karyopharm : DSMB Recommends Phase 3 Study On Endometrial Cancer Should Proceed As Planned Without Any Modifications
11/12/2020 7:56:16 PM
Karyopharm Announces Publication Of XPOVIO Phase 3 BOSTON Study Results
11/3/2020 8:11:25 AM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/6/2020 8:15:36 AM
Karyopharm Reveals Promising Results On Low Dose Selinexor In Hospitalized Patients With Severe COVID-19
8/31/2020 7:04:04 AM
Karyopharm Therapeutics Appoints Christy Oliger To Board
8/4/2020 7:08:49 AM
Karyopharm Therapeutics Q2 Net Loss $46.4 Mln Or $0.63/shr Vs. Net Loss $43.4 Mln Or $0.71/shr Last Year
7/20/2020 7:22:33 AM
Karyopharm: FDA Accept SNDA For XPOVIO For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy
7/14/2020 7:16:34 AM
Karyopharm Expects Net Product Sales Of XPOVIO To Be $18.5 Mln For Q2
6/24/2020 7:16:44 AM
Karyopharm Publishes XPOVIO Phase 2b SADAL Study Results In The Lancet Haematology